[go: up one dir, main page]

LU91381I2 - OPTAFLU-Définition du produit: Vaccin grippal préparé à partir du virus de la grippe dans une culture celluluaire ou les cellules sont cultivées à unetempérature comprise entre 30°C et 36°C pour la r éplication des virus - Google Patents

OPTAFLU-Définition du produit: Vaccin grippal préparé à partir du virus de la grippe dans une culture celluluaire ou les cellules sont cultivées à unetempérature comprise entre 30°C et 36°C pour la r éplication des virus

Info

Publication number
LU91381I2
LU91381I2 LU91381C LU91381C LU91381I2 LU 91381 I2 LU91381 I2 LU 91381I2 LU 91381 C LU91381 C LU 91381C LU 91381 C LU91381 C LU 91381C LU 91381 I2 LU91381 I2 LU 91381I2
Authority
LU
Luxembourg
Prior art keywords
replication
cell culture
viruses
optaflu
cultured
Prior art date
Application number
LU91381C
Other languages
English (en)
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7790127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91381(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of LU91381I2 publication Critical patent/LU91381I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LU91381C 1996-04-01 2007-11-30 OPTAFLU-Définition du produit: Vaccin grippal préparé à partir du virus de la grippe dans une culture celluluaire ou les cellules sont cultivées à unetempérature comprise entre 30°C et 36°C pour la r éplication des virus LU91381I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19612967A DE19612967A1 (de) 1996-04-01 1996-04-01 Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
PCT/IB1997/000404 WO1997037001A1 (fr) 1996-04-01 1997-04-01 Procedes de replication des virus de la grippe dans une culture cellulaire, et virus de la grippe obtenus selon ce procede

Publications (1)

Publication Number Publication Date
LU91381I2 true LU91381I2 (fr) 2008-01-30

Family

ID=7790127

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91381C LU91381I2 (fr) 1996-04-01 2007-11-30 OPTAFLU-Définition du produit: Vaccin grippal préparé à partir du virus de la grippe dans une culture celluluaire ou les cellules sont cultivées à unetempérature comprise entre 30°C et 36°C pour la r éplication des virus

Country Status (12)

Country Link
US (2) US20030119183A1 (fr)
EP (3) EP1526172B1 (fr)
JP (6) JP4447054B2 (fr)
AT (2) ATE513905T1 (fr)
CA (1) CA2250078C (fr)
DE (3) DE19612967A1 (fr)
DK (2) DK1526172T3 (fr)
ES (3) ES2367081T3 (fr)
LU (1) LU91381I2 (fr)
NL (1) NL300307I1 (fr)
PT (2) PT1526172E (fr)
WO (1) WO1997037001A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
JP2001521736A (ja) * 1997-10-31 2001-11-13 メルク エンド カムパニー インコーポレーテッド 回転瓶内の混合増進方法
EP1027426A4 (fr) * 1997-10-31 2006-04-19 Merck & Co Inc Procede de melange ameliore d'une culture cellulaire infectee par la varicelle dans une bouteille pour agitateur rotatif
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
AU3604201A (en) 2000-03-03 2001-09-12 Chemo Sero Therapeut Res Inst Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
MXPA04004726A (es) * 2001-11-19 2004-07-30 Becton Dickinson Co Composiciones farmaceuticas en forma particulada.
US7635575B2 (en) 2002-09-16 2009-12-22 Pan-Biotech Gmbh Method for cultivating cells, particularly human or animal cells
WO2004033616A1 (fr) * 2002-09-16 2004-04-22 Pan-Biotech Gmbh Dispositif de mise en culture de cellules, notamment de cellules humaines ou animales
MXPA05005306A (es) 2003-06-20 2005-10-26 Microbix Biosystems Inc Mejoramientos en la produccion de virus.
WO2005107797A1 (fr) 2004-03-09 2005-11-17 Chiron Corporation Vaccins antigrippaux
WO2005113758A1 (fr) * 2004-05-20 2005-12-01 Id Biomedical Corporation Procédé pour la fabrication d’un vaccin contre la grippe
EP2848692B1 (fr) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Vecteurs d'alphavirus de vaccins contre le virus de la grippe
SI2578229T1 (sl) * 2004-09-09 2013-10-30 Novartis Vaccines And Diagnostics Gmbh Zmanjšanje potencialnih iatrogenih tveganj, povezanih z antigeni cepiv
CA2593036A1 (fr) 2004-12-08 2006-06-15 Medimmune Vaccines, Inc. Methodes de preparation de vaccins contre la grippe
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
EA014062B1 (ru) 2005-11-01 2010-08-30 Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг Вирусные вакцины, полученные из клеток с низкими уровнями остаточной клеточной днк
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PL1945252T3 (pl) * 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
NZ568210A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
WO2007085969A2 (fr) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Vaccins contre la grippe contenant des hémaglutinines et des protéines matricielles
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
CN101472941B (zh) 2006-03-31 2017-08-08 沃弗-威斯康星校友研究基金会 用于疫苗的高滴度重组流感病毒
US7883844B2 (en) 2006-05-11 2011-02-08 Juridical Foundation The Chemosero-Therapeutic Research Institute Method for propagating influenza virus
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
JP5954921B2 (ja) 2006-09-11 2016-07-20 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
AU2007347716B2 (en) 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
WO2008068631A2 (fr) 2006-12-06 2008-06-12 Novartis Ag Vaccins comprenant un antigène issu de quatre souches du virus grippal
CN101688186A (zh) * 2007-05-04 2010-03-31 巴克斯特国际公司 用于病毒增殖的两阶段温度分布
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
RU2547587C2 (ru) 2008-09-24 2015-04-10 Медиммун, Ллк Способы культивирования клеток, размножения и очистки вирусов
CA2752041A1 (fr) 2009-02-10 2010-08-19 Novartis Ag Vaccins contre l'influenza possedant des quantites accrues d'antigene h3
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
KR20110132373A (ko) 2009-02-10 2011-12-07 노파르티스 아게 유행병-연관 주에 대한 인플루엔자 백신 요법
WO2010125461A1 (fr) 2009-04-27 2010-11-04 Novartis Ag Vaccins avec adjuvants pour protéger du virus de la grippe
AU2010250832B2 (en) 2009-05-21 2013-10-03 Seqirus UK Limited Reverse genetics using non-endogenous pol I promoters
WO2010144797A2 (fr) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations
EP2459722B1 (fr) 2009-07-31 2017-09-06 Seqirus UK Limited Systemes de genetique inverse
EP2475385A1 (fr) 2009-09-10 2012-07-18 Novartis AG Vaccins combinés contre les maladies des voies respiratoires
US8883481B2 (en) 2009-10-20 2014-11-11 Novartis Ag Reverse genetics methods for virus rescue
EP2493912B1 (fr) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation Virus recombinants de la grippe de titre élevé à réplication améliorée dans les cellules vero
WO2011095596A1 (fr) 2010-02-04 2011-08-11 Vivalis Procédé à alimentation discontinue utilisant un milieu de culture de cellules concentré pour la production efficace de produits biologiques dans des cellules eb66
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2563909A1 (fr) 2010-04-26 2013-03-06 Novartis AG Production améliorée de particules de réplicon de virus dans des cellules d'encapsidation
US8945904B2 (en) 2010-05-21 2015-02-03 Novartis Ag Influenza virus reassortment
KR20130081659A (ko) 2010-06-01 2013-07-17 노파르티스 아게 인플루엔자 백신 항원의 농축 및 동결건조
EP2575872B1 (fr) 2010-06-01 2020-08-19 Seqirus UK Limited Concentration d'antigènes de vaccin sans lyophilisation
CA2808965C (fr) 2010-08-20 2020-01-07 Novartis Ag Ensembles d'aiguilles solubles pour l'administration de vaccins contre la grippe
EP3520813B1 (fr) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Plateformes de délivrance d'antigènes
LT2667892T (lt) 2011-01-26 2019-05-10 Glaxosmithkline Biologicals Sa Rsv imunizacijos režimas
US9879229B2 (en) 2011-03-14 2018-01-30 National Research Council Of Canada Method of viral production in cells
WO2013032942A1 (fr) 2011-08-26 2013-03-07 Yoshihiro Kawaoka Virus de la grippe ayant un segment génique pb2 mutant en tant que vaccins vivants atténués
CA2872033A1 (fr) 2011-10-11 2013-04-18 Novartis Ag Molecules recombinantes d'arn polycistronique a autoreplication
EP2766385A2 (fr) 2011-10-12 2014-08-20 Novartis AG Antigènes de cmv et leurs utilisations
CA2852857A1 (fr) 2011-10-20 2013-04-25 Novartis Ag Vaccins avec adjuvant contre le virus grippal b pour primo-vaccination pediatrique
CN103608453B (zh) 2012-03-02 2018-07-24 思齐乐 流感病毒重配
RU2599496C2 (ru) 2012-03-06 2016-10-10 Круселл Холланд Б.В. Улучшенная вакцинация против гриппа
CA2875752A1 (fr) 2012-06-04 2013-12-12 Novartis Ag Test de securite ameliore
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
HK1214959A1 (zh) 2012-12-03 2016-08-12 Novartis Ag 流感病毒重配
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment
AU2014264501A1 (en) 2013-05-10 2015-12-10 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
US10329537B2 (en) 2013-06-06 2019-06-25 Seqirus UK Limited Influenza virus reassortment
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015196150A2 (fr) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
CN108027371B (zh) 2015-07-07 2020-08-18 思齐乐 流感效力试验
CA3014435C (fr) 2016-02-19 2023-04-18 Wisconsin Alumni Research Foundation (Warf) Replication amelioree du virus de la grippe b pour l'elaboration de vaccin
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
CA3081578A1 (fr) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Vaccins et compositions immunogenes anti-zika, et leurs procedes d'utilisation
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
WO2020041311A1 (fr) 2018-08-20 2020-02-27 Wisconsin Alumni Research Foundation Vecteurs pour induire des réponses immunitaires à des épitopes non dominants dans la protéine hémagglutinine (ha)
EP3914295A2 (fr) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (fr) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Réplication améliorée du virus de la grippe pour l'élaboration de vaccin
CA3137652A1 (fr) 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Compositions de virus inactive et formulations de vaccin a base de zika
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
EP4061930A1 (fr) 2019-11-18 2022-09-28 Seqirus Pty Ltd Procédé de production de virus de la grippe réassortis
US11739303B2 (en) 2020-01-24 2023-08-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized NA
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법
WO2023154043A1 (fr) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Vaccins contre le zika et compositions immunogènes, et procédés d'utilisation associés

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278075B (de) * 1964-06-22 1968-09-19 Norden Lab Inc Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
CA1122527A (fr) * 1979-05-15 1982-04-27 Karen K. Brown Production d'un vaccin contre l'influenza par culture de cellules en milieu liquide
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5646033A (en) * 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6514502B1 (en) * 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells

Also Published As

Publication number Publication date
DE19612967A1 (de) 1997-10-02
DE69732407T3 (de) 2014-07-10
JP2006296437A (ja) 2006-11-02
JP2000507825A (ja) 2000-06-27
JP2008245659A (ja) 2008-10-16
DE122007000082I1 (de) 2009-01-02
EP2172543A1 (fr) 2010-04-07
EP1526172A1 (fr) 2005-04-27
EP2172543B1 (fr) 2013-08-21
ES2435726T3 (es) 2013-12-23
JP2010275321A (ja) 2010-12-09
JP2013116124A (ja) 2013-06-13
ES2367081T3 (es) 2011-10-28
US20030119183A1 (en) 2003-06-26
DE69732407D1 (de) 2005-03-10
ES2236799T3 (es) 2005-07-16
HK1075467A1 (en) 2005-12-16
PT1526172E (pt) 2011-09-01
PT891420E (pt) 2005-06-30
ES2236799T5 (es) 2014-01-23
WO1997037001A1 (fr) 1997-10-09
DK1526172T3 (da) 2011-10-03
CA2250078A1 (fr) 1997-10-09
DE69732407T2 (de) 2006-01-19
DK0891420T3 (da) 2005-04-25
NL300307I1 (nl) 2008-02-01
EP1526172B1 (fr) 2011-06-22
EP0891420A1 (fr) 1999-01-20
US20070117131A1 (en) 2007-05-24
HK1142093A1 (en) 2010-11-26
JP4447054B2 (ja) 2010-04-07
EP0891420B2 (fr) 2013-11-20
CA2250078C (fr) 2009-06-23
JP5264843B2 (ja) 2013-08-14
DK0891420T4 (da) 2014-01-20
JP2011212020A (ja) 2011-10-27
EP0891420B1 (fr) 2005-02-02
ATE513905T1 (de) 2011-07-15
ATE288479T1 (de) 2005-02-15

Similar Documents

Publication Publication Date Title
LU91381I2 (fr) OPTAFLU-Définition du produit: Vaccin grippal préparé à partir du virus de la grippe dans une culture celluluaire ou les cellules sont cultivées à unetempérature comprise entre 30°C et 36°C pour la r éplication des virus
US5447915A (en) Terminally blocked antiviral peptides
EA200200604A1 (ru) Производство вакцин
ATE466932T1 (de) Vermehrung von viren in zellkultur
Andersson et al. Activated human T lymphocytes display new surface glycoproteins.
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
Gething et al. Fusion of Sendai virus with the target cell membrane is required for T cell cytotoxicity
Martin et al. HLA-DR, ICAM-1, CD40, CD40L, and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex vivo
DK0480949T3 (da) Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse
JPH114685A (ja) 冬眠特異的タンパク質産生樹立細胞株およびその創製方法
Vestergárd Jørgensen Indirect fluorescent antibody techniques for demonstration of trout viruses and corresponding antibody
Young et al. A foamy virus of possible human origin isolated in BHK-21 cells
BR0307512A (pt) Métodos para produzir uma linhagem de células contìnua, para gerar e/ou isolar e/ou manter uma cepa de vìrus da doença de marek, para produzir um antìgeno diagnóstico de um vìrus da doença de marek, para preparar uma vacina capaz de induzir proteção contra doença em um vertebrado, e para proteger um vertebrado contra doença, célula ou sua prole, preparação de células, uso das mesmas, vacina, e, uso da mesma
DE60143810D1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
Miller et al. Monoclonal antibody to Lyt 2 antigen blocks H–2I-and H–2K-specific mouse cytotoxic T cells
RU95117092A (ru) Антитела, смесь антител, fab-фрагмент, линии гибридомных клеток, способы создания линий клеток, способ борьбы с вирусом, способ снижения уровня антигена, днк
ATE345814T1 (de) Herstellung eines chimeren papillomavirus
Sethi et al. Cytolytic human T-cell clones expressing Epstein-Barr virus specificity and HLA restriction
TH35753C3 (th) อิมมูโนเจนที่ถูกเพิ่มกำลัง สำหรับวัคซีนเชื้อตายเพื่อต่อสู้กับโรคที่เป็นการติดเชื้อ ที่มีสาเหตุมาจากกลุ่มของเจเปเนส เอนซีฟาไลทีสไวรัสและวิธีการเพื่อผลิตสิ่งนั้น
Kaneko et al. Cytotoxic T lymphocytes to murine plasmacytoma cells in allogeneic and syngeneic mice: H-2 antigens are essential in the induction and effector stages of CTL
Sabesin The Role of Lysosomes in the Pathogenesis of Experimental Viral Hepatitis∗†.
Bell et al. Effect of herpes simplex virus on human embryonic cells latently infected with reovirus type 3
Rossier Studies on the immunogenicity of virus-infected lymphocytes for the production of antilymphocyte serum
JP2005524707A (ja) 核酸の修飾のための方法および組成物
Weller et al. RECEPTION OF PSEUDORABIES VIRUS ANTIGEN FOR USE IN AUJESZKY’S DISEASE DIAGNOSIS